Omeros Return on Tangible Equity 2010-2024 | OMER
Current and historical return on tangible equity values for Omeros (OMER) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Omeros Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-09-30 | $-0.13B | $-0.15B | 142.93% |
| 2024-06-30 | $-0.14B | $-0.13B | 238.30% |
| 2024-03-31 | $-0.12B | $-0.07B | 543.82% |
| 2023-12-31 | $-0.12B | $-0.03B | -1275.68% |
| 2023-09-30 | $0.02B | $-0.01B | 54.05% |
| 2023-06-30 | $0.04B | $0.02B | 141.38% |
| 2023-03-31 | $0.05B | $0.06B | 303.23% |
| 2022-12-31 | $0.05B | $0.09B | 9600.00% |
| 2022-09-30 | $0.20B | $-0.05B | -1333.33% |
| 2022-06-30 | $0.19B | $-0.03B | -280.14% |
| 2022-03-31 | $0.20B | $-0.01B | -160.00% |
| 2021-12-31 | $0.19B | $0.02B | -109.76% |
| 2021-09-30 | $-0.12B | $-0.26B | 58.22% |
| 2021-06-30 | $-0.14B | $-0.25B | 82.25% |
| 2021-03-31 | $-0.14B | $-0.22B | 96.79% |
| 2020-12-31 | $-0.14B | $-0.12B | 109.38% |
| 2020-09-30 | $-0.13B | $-0.09B | 105.52% |
| 2020-06-30 | $-0.11B | $-0.16B | 78.97% |
| 2020-03-31 | $-0.09B | $-0.13B | 68.88% |
| 2019-12-31 | $-0.08B | $-0.11B | 66.40% |
| 2019-09-30 | $-0.08B | $-0.14B | 63.54% |
| 2019-06-30 | $-0.10B | $-0.13B | 91.82% |
| 2019-03-31 | $-0.12B | $-0.12B | 132.24% |
| 2018-12-31 | $-0.13B | $-0.10B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.09B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.06B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.03B | 348.72% |
| 2017-12-31 | $-0.05B | $-0.00B | 218.56% |
| 2017-09-30 | $-0.06B | $0.01B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.06B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.05B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.02B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.05B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.04B | 458.82% |
| 2015-12-31 | $-0.08B | $-0.03B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.04B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.03B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.02B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $-0.00B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.02B | 388.89% |
| 2012-03-31 | $-0.03B | $-0.01B | 2480.00% |
| 2011-12-31 | $-0.03B | $-0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.00B | -212.24% |
| 2011-06-30 | $-0.03B | $0.01B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.02B | -109.09% |
| 2010-09-30 | $-0.03B | $0.02B | -87.22% |
| 2010-06-30 | $-0.03B | $0.03B | -104.17% |
| 2010-03-31 | $-0.02B | $0.04B | -139.39% |
| 2009-12-31 | $-0.02B | $0.04B | -289.66% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.593B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $194.987B | 24.87 |
| Stryker (SYK) | United States | $136.147B | 30.68 |
| Boston Scientific (BSX) | United States | $130.670B | 37.57 |
| EssilorLuxottica (ESLOY) | France | $110.026B | 0.00 |
| Medtronic (MDT) | Ireland | $102.570B | 15.24 |
| Haleon (HLN) | United Kingdom | $43.909B | 28.53 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.293B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $35.376B | 18.35 |
| ResMed (RMD) | United States | $33.995B | 27.93 |
| Terumo (TRUMY) | Japan | $28.800B | 40.67 |
| Koninklijke Philips (PHG) | Netherlands | $23.527B | 18.01 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.064B | 13.41 |
| Insulet (PODD) | United States | $17.996B | 71.67 |
| Baxter (BAX) | United States | $14.756B | 9.60 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.838B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.021B | 40.32 |
| Bio-Rad Laboratories (BIO) | United States | $9.125B | 31.01 |
| Demant (WILYY) | Denmark | $7.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.392B | 14.85 |
| Prestige Consumer Healthcare (PBH) | United States | $3.886B | 19.33 |
| Haemonetics (HAE) | United States | $3.862B | 18.85 |
| ICU Medical (ICUI) | United States | $3.751B | 35.71 |
| Perrigo (PRGO) | Ireland | $3.510B | 10.33 |
| Envista Holdings (NVST) | United States | $3.103B | 23.11 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.894B | 18.63 |
| GN Store Nord (GNNDY) | Denmark | $2.864B | 18.36 |
| Neogen (NEOG) | United States | $2.605B | 30.05 |
| LeMaitre Vascular (LMAT) | United States | $2.074B | 50.41 |
| Green Thumb Industries (GTBIF) | United States | $1.630B | 28.52 |
| AtriCure (ATRC) | United States | $1.465B | 0.00 |
| InMode (INMD) | Israel | $1.444B | 8.68 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.371B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.304B | 9.32 |
| BioLife Solutions (BLFS) | United States | $1.211B | 0.00 |
| Owens & Minor (OMI) | United States | $0.973B | 7.60 |
| CeriBell (CBLL) | United States | $0.958B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.955B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.883B | 15.58 |
| Evolus (EOLS) | United States | $0.688B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.593B | 26.15 |
| Capricor Therapeutics (CAPR) | United States | $0.587B | 0.00 |
| Surmodics (SRDX) | United States | $0.572B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.445B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.429B | 0.00 |
| Quanterix (QTRX) | United States | $0.383B | 0.00 |
| ZimVie (ZIMV) | United States | $0.373B | 31.44 |
| Valneva SE (VALN) | France | $0.353B | 0.00 |
| Biote (BTMD) | United States | $0.313B | 6.86 |
| Viemed Healthcare (VMD) | United States | $0.312B | 29.70 |
| Canopy Growth (CGC) | Canada | $0.295B | 0.00 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.283B | 18.95 |
| Sanara MedTech (SMTI) | United States | $0.276B | 0.00 |
| Zynex (ZYXI) | United States | $0.268B | 56.00 |
| High Tide (HITI) | Canada | $0.237B | 98.00 |
| Aurora Cannabis (ACB) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.211B | 14.54 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Organigram Holdings (OGI) | Canada | $0.184B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.181B | 0.00 |
| Brainsway (BWAY) | Israel | $0.169B | 89.60 |
| FitLife Brands (FTLF) | United States | $0.151B | 19.04 |
| Jin Medical (ZJYL) | China | $0.132B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.110B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.79 |
| Veru (VERU) | United States | $0.092B | 0.00 |
| Exagen (XGN) | United States | $0.083B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.066B | 34.17 |
| InterCure (INCR) | Israel | $0.061B | 0.00 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.054B | 0.00 |
| Modular Medical (MODD) | United States | $0.050B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.042B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.82 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |